Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective

Yao Zhang; Yibing Wang; Junli Liu

doi:10.1016/j.gendis.2021.12.011

您当前的位置：

首页 >

文章列表页 >

Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective

Review article | 更新时间：2023-08-29

- Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
- Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
- Genes & Diseases 2023年10卷第3期
- 作者机构：
  
  1. Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Shanghai,China,200233
  2. School of Kinesiology, Shanghai University of Sport,Shanghai,China,200438
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2021.12.011
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-5-1，
扫描看全文
Yao Zhang, Yibing Wang, Junli Liu. Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective[J]. Genes & Diseases, 2023,10(3).

Yao Zhang, Yibing Wang, Junli Liu. Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective[J]. Genes & Diseases, 2023,10(3).
Yao Zhang, Yibing Wang, Junli Liu. Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective[J]. Genes & Diseases, 2023,10(3). DOI： 10.1016/j.gendis.2021.12.011.

Yao Zhang, Yibing Wang, Junli Liu. Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective[J]. Genes & Diseases, 2023,10(3). DOI： 10.1016/j.gendis.2021.12.011.

摘要

Abstract

Due to excess energy intake and a sedentary lifestyle

the prevalence of obesity is rising steadily and has emerged as a global public health problem. Adipose tissue undergoes structural remodeling and dysfunction in the obese state. Secreted proteins derived from the liver

also termed as hepatokines

exert multiple effects on adipose tissue remodeling and the development of obesity

and has drawn extensive attention for their therapeutic potential in the treatment of obesity and related diseases. Several novel hepatokines and their functions on systemic metabolism have been interrogated recently as well. The drug development programs targeting hepatokines also have shown inspiring benefits in obesity treatment. In this review

we outline how adipose tissue changes during obesity. Then

we summarize and critically analyze the novel findings on the effects of metabolic “beneficial” and metabolic “harmful” hepatokines to adipose tissue. We also discuss the in-depth molecular mechanism that hepatokines may mediate the liver-adipose tissue crosstalk

the novel technologies targeting hepatokines and their receptors

in vivo

to explore their functions

and the potential application of these interventions in clinical practice.

关键词

Keywords

FGF21HepatokineLiver-adipose tissue crosstalkObesityTherapeutic strategy

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Multiple regulatory roles of the transfer RNA-derived small RNAs in cancers

The journey towards physiology and pathology: Tracing the path of neuregulin 4

Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network

New insight of obesity-associated NAFLD: Dysregulated “crosstalk” between multi-organ and the liver?

Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases